Literature DB >> 32972216

Characterization of a Novel HIV-1 CRF01_AE/CRF07_BC Recombinant Strain Among Men Who Have Sex with Men in Liaoning, China.

Shan He1,2,3, Yang Gao1,2,3, Minghui An1,2,3, Bin Zhao1,2,3, Lin Wang1,2,3, Haibo Ding1,2,3, Xiaoxu Han1,2,3.   

Abstract

CRF01_AE and CRF07_BC are two widespread human immunodeficiency virus type 1 (HIV-1) strains among different high-risk populations, including men who have sex with men (MSM), in China. This co-epidemic of various HIV strains enables the production of second-generation recombinants. In this study, we detected a novel HIV-1 CRF01_AE/CRF07_BC recombinant from LN321945, an MSM lived in Liaoning province, northeast China. The phylogenetic and recombination analyses indicated the near full-length genome (NFLG) sequence of LN321945 had six recombination breakpoints, with three CRF07_BC fragments inserted into a CRF01_AE backbone. Further subregion trees analysis revealed that both CRF01_AE and CRF07_BC fragments were derived from two predominant HIV-1 strains among MSM. In addition, the NFLG of LN321945 was revealed to be clustered closely to another CRF01_AE/CRF07_BC recombinant previously identified in Shaanxi province, northwest China, but these two recombinants had distinct recombination structure and origin of CRF01_AE fragments. Hence, this study identified a second-generation recombinant between the main strains circulating among MSM, indicating more complicated trend of HIV-1 epidemic in China.

Entities:  

Keywords:  CRF01_AE; CRF07_BC; HIV-1; unique recombinant form

Year:  2020        PMID: 32972216     DOI: 10.1089/AID.2020.0223

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  1 in total

1.  Multiple CRF01_AE/CRF07_BC Recombinants Enhanced the HIV-1 Epidemic Complexity Among MSM in Shenyang City, Northeast China.

Authors:  Shan He; Wei Song; Gang Guo; Qiang Li; Minghui An; Bin Zhao; Yang Gao; Wen Tian; Lin Wang; Hong Shang; Xiaoxu Han
Journal:  Front Microbiol       Date:  2022-05-12       Impact factor: 6.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.